ClinicalTrials.gg
RecruitingNCT07670130ND-AMLUpdated Aug 6, 2026

Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis

An observational study in Acute Myeloid Leukemia (AML), sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by The First Affiliated Hospital of Soochow University · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 57 studies in Leukemia, Myeloid, Acute by The First Affiliated Hospital of Soochow University — 30 open to participants now, 34 under way, 6 of them phase 3. Leukemia, Myeloid, Acute · The First Affiliated Hospital of Soochow University.

Started
2026
with 10 others
Observational
6 of 57
2 open now
Primary completion
2027-06
later than 16 of 33 live
Registered
55th of 57
by date

Among the 57 studies in Leukemia, Myeloid, Acute by The First Affiliated Hospital of Soochow University, this one is one of 11 that started in 2026, is one of 6 observational ones, reaches primary completion later than 16 of the 33 other live ones, and was the 55th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

30 of the 57 studies in Leukemia, Myeloid, Acute by The First Affiliated Hospital of Soochow University are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Leukemia, Myeloid, Acute by The First Affiliated Hospital of Soochow University, or all of them as a file.
02

Study summary

Venetoclax combined with azacitidine (VEN-AZA) is the current first-line standard of care for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. Although this regimen substantially improves remission rates, marked inter-individual variability is observed in clinical practice-ranging from severe myelosuppression or tumor lysis syndrome in some patients to poor response or early relapse in others. Venetoclax is primarily metabolized by CYP3A4, and its systemic exposure is modulated by multiple factors, including hepatic and renal function, concomitant medications (particularly azole antifungals), and UGT1A1 polymorphisms, leading to a 50%-70% inter-individual variability in blood drug concentrations.

Despite this variability, the current VEN-AZA regimen employs a fixed-dose strategy (400 mg/day) without incorporating therapeutic drug monitoring (TDM) to guide individual dosing. Critical knowledge gaps remain: (1) whether a clear exposure-response relationship exists between venetoclax exposure and composite remission rate (CR+CRi); (2) what blood concentration range optimizes efficacy while minimizing toxicity; (3) which covariates significantly influence venetoclax clearance; and (4) whether early concentration sampling can reliably predict subsequent exposure and clinical outcomes.*

To address these questions, investigators designed a prospective study enrolling newly diagnosed AML patients receiving VEN-AZA therapy. Investigators aim to systematically characterize the exposure-response relationship, establish an optimal therapeutic concentration window, identify key covariates contributing to inter-individual pharmacokinetic variability, and evaluate early-sampling prediction strategies. The findings are expected to provide direct evidence for TDM-guided individualized dosing and to support a paradigm shift from a "fixed-dose" to a "concentration-guided" approach in precision AML therapy.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This prospective study included newly diagnosed AML patients who received the venetoclax plus azacitidine as induction. Venetoclax concentration data were collected on days 8, 15, and 22, and the steady-state trough concentration (Cmin), peak concentration (Cmax), and area under the curve (AUC) were calculated. The relationships between venetoclax exposure levels (Cmax, Cmin, and AUC) and efficacy, safety, survival, and individual patient characteristics were analyzed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis: Newly diagnosed acute myeloid leukemia (AML) confirmed according to the WHO 2022 or International Consensus Classification (ICC) criteria, based on bone marrow morphology, flow cytometry, and molecular genetics. Acute promyelocytic leukemia (APL) is excluded.
  2. Treatment regimen: Planned or already initiated therapy with venetoclax plus azacitidine (VEN-AZA), with dosing determined by the treating physician according to routine clinical practice (no protocol-mandated dose restrictions).
  3. Age: ≥ 16 years.
  4. : Willingness and ability to provide written informed consent for participation in this observational study.
  5. Follow-up: Agreement to attend scheduled follow-up visits and to permit clinical data collection at the time points specified in the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Prior AML therapy: Prior treatment for AML, with the exception of leukapheresis, hydroxyurea, low-dose cytarabine, or .
  2. Concurrent interventional trials: Current participation in any interventional clinical trial, including those involving agents.
  3. Extremely short : Judged by the investigator to be unable to complete at least one full cycle of therapy and the associated follow-up.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Venetoclax combined with Azacitidine

    ND-AML patients received the venetoclax plus azacitidine as induction. Dosage is determined by clinicians based on routine practice (not mandatory in the study protocol). Venetoclax concentration data were collected on days 8, 15, and 22, and the steady-state trough concentration (Cmin), peak concentration (Cmax), and area under the curve (AUC) were calculated.

06

What researchers measure

Primary outcomes

  1. Complete remission rate

    Percentage of subjects with complete remission (CR) and incomplete hematologic recovery (CRi)

    Time frame: At the end of induction treatment (28 days ± 7days)

Secondary outcomes

  1. Hematological toxicity

    Number of subjects with hematological adverse events

    Time frame: Start of treatment to 2 weeks after end of treatment

  2. Non-hematological toxicity

    Number of subjects with non-hematological adverse events

    Time frame: Start of treatment to 2 weeks after end of treatment

  3. Overall Survival

    From start of induction treatment to time of death due to any cause, or until last follow-up

    Time frame: 24 months

  4. Event-free Survival

    From start of induction treatment to time of disease relapse/progression or death due to any cause, whichever occurs earlier; or until last follow-up

    Time frame: 24 months

  5. Measurable residual disease response rate

    Percentage of subjects with MRD negative

    Time frame: At the end of induction treatment (28 days ± 7days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's planned 12 months is below that.

Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jun 26, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07670130
Responsible party
CHEN Jia (Chief Physician of Hematology. Clinical Professor. Principal Investigator, The First Affiliated Hospital of Soochow University) — Principal investigator
First posted
Jun 26, 2026
Start date
Jun 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Jia Chen
Contact
drchenjia@163.com
86+052167976801

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion